Company Profile
Theravance Biopharma Stock Price, News & Analysis
Company overview
Business overview
Theravance Biopharma is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Theravance Biopharma is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Theravance Biopharma follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Theravance Biopharma sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
TBPH is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Theravance is in a transition phase after the CYPRESS outcome, and the company is now leaning into restructuring and strategic review work. The key thing to watch is whether the cost action really changes the shape of the business or just buys more time.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
Source: Theravance Biopharma
- 02
Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Source: Theravance Biopharma
- 03
- 04
- 05
Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025
Source: Theravance Biopharma
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.